New research has suggested that recommended vaccinia virus (VACV)-based vaccines will mount a robust immune response against the monkeypox virus observed in the current outbreak (MPXV-2022).
A new study published in the Viruses journal aimed to investigate the cross-reactivity of VACV-based vaccines against the MPXV viruses responsible for the 2022 outbreak.
Researchers performed an analysis of molecular variance in 59 haplotypes of the IFNAR gene, departing from monkeypox virus, camelpox virus, buffalopox virus, ectromelia virus, cowpox virus, rabbitpox virus, variola virus, and vaccinia virus.